Fate has announced the retirement of president and CEO Scott Wolchko with Bob Valamehr set to assume the role from 1 January ...

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.

The research team at UQ has secured a grant of $344,000 from the National Foundation for Medical Research and Innovation.

CBC Group has completed the strategic acquisition of UCB's mature neurology and allergy business in China for $680m.

The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive ...

The ESMP platform enables marketing authorisation holders to report shortages and will be mandatory from 2025.

University of Birmingham researchers have identified CD70 as a key target to reduce the risk of GVHD in blood cancer patients ...

Meningitis C cases are down 99% since the NHS routine vaccination programme was introduced by UKHSA and NHS England in 1999.

Allink Biotherapeutics has completed a $42m Series A financing round to expedite the worldwide development of its ADC ...

China’s NMPA has approved MSD’s WELIREG (belzutifan) to treat adult individuals with certain types of VHL disease-associated ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

The relationship between climate change and infectious disease is raising new questions for pharmaceutical and clinical ...